Candriam SCA’s Lumos Pharma, Inc. Common Stock LUMO Stock Holding History

Candriam SCA’s Portfolio LUMO Stock Details LUMO Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2018 Q4	–	Sell	-27,556	Closed	-$593K	–	853
2018 Q3	$593K	Sell	27,556 -5,000	-15%	-$152K	0.01%	694
2018 Q2	$1.4M	Hold	32,556	–	–	0.02%	549
2018 Q1	$2.12M	Hold	32,556	–	–	0.04%	467
2017 Q4	$2.38M	Sell	32,556 -3,888	-11%	-$322K	0.04%	421
2017 Q3	$3.34M	Buy	36,444 +28,111	+337%	+$2.16M	0.06%	352
2017 Q2	$551K	Buy	+8,333	New	+$1.03M	0.01%	652
2017 Q1	–	Sell	-2,778	Closed	-$257K	–	711
2016 Q4	$257K	Buy	+2,778	New	+$313K	0.01%	644
2015 Q3	–	Sell	-4,333	Closed	-$1.73M	–	650
2015 Q2	$1.73M	Sell	4,333 -6,778	-61%	-$2.88M	0.04%	380
2015 Q1	$5.47M	Sell	11,111 -8,889	-44%	-$3.44M	0.11%	239
2014 Q4	$7.16M	Buy	+20,000	New	+$5.95M	0.15%	189

Other funds holding LUMO

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

PAM

Panagora Asset Management Boston, Massachusetts $26.7B AUM 36.4% 1-Year Est. Return

Connor, Clark & Lunn Investment Management (CC&L) Vancouver, British Columbia, Canada $43.4B AUM 51.29% 1-Year Est. Return

OAM

Oxford Asset Management Oxford, United Kingdom $232M AUM 31% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Wells Fargo San Francisco, California $530B AUM 22.01% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Candriam SCA's LUMO Position: Q4 2018 in Review

Candriam SCA sold out of Lumos Pharma, Inc. Common Stock (LUMO) in Q4 2018, closing a stake of 27,556 shares — an estimated $593K sold.

Candriam SCA first reported a position in LUMO in Q4 2014 and held it in 10 quarters. The position peaked at $7.16M in Q4 2014. 87 funds tracked by Wall St. Rank hold LUMO as of Q4 2018.

Candriam SCA reported no remaining Lumos Pharma, Inc. Common Stock position as of Q4 2018 after selling out during the quarter.
Candriam SCA sold 27,556 Lumos Pharma, Inc. Common Stock shares in Q4 2018, an estimated $593K.
Candriam SCA first reported a position in Lumos Pharma, Inc. Common Stock in Q4 2014 and held it in 10 quarters.
Candriam SCA's Lumos Pharma, Inc. Common Stock position peaked at $7.16M in Q4 2014.
87 funds tracked by Wall St. Rank held Lumos Pharma, Inc. Common Stock as of Q4 2018.

Based on Candriam SCA's 13F filing for Q4 2018, filed 14 Feb 2019.